2026 · 3rd Quarter (July 1 - Sep 30)

JAZZ PHARMACEUTICALS, INC.

Filed by JAZZ PHARMACEUTICALS, INC..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: Not reported
Expenses: $550,000.00
Registrant: JAZZ PHARMACEUTICALS, INC.
Client: JAZZ PHARMACEUTICALS, INC.
Filing UUID: 899fafff-4a40-4417-9a39-16e47d19935f
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act Legislation Related to the Repeal or Reform of Orphan Cures Section 232 Tariffs

Literal federal measure citations: HR 946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.